Is cabozantinib an anti-angiogenic drug?

Yes, cabozantinib (Cabozantinib) is an anti-angiogenic drug. It works by inhibiting multiple receptor tyrosine kinases (RTKs), including MET (hepatocyte growth factor receptor), VEGFR (vascular endothelial growth factor receptor), RET (rearranged cancer) Gene family receptor kinase), KIT (cytoplasmic tyrosine kinase) and AXL (axon-associated protein kinase), etc., as well as the inhibition of the vascular endothelial growth factor (VEGF) signaling pathway, thereby inhibiting the growth and metastasis of tumor cells and reducing the formation of tumor neovascularization. This anti-angiogenic effect helps reduce the blood supply to the tumor and reduce the nutrient supply to the tumor, thereby inhibiting tumor growth and spread. Therefore, cabozantinib is widely used to treat many types of cancer, including renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma.